PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours

MLA

Martin Forster, et al. “PATRIOT: A Phase I Study to Assess the Tolerability, Safety and Biological Effects of a Specific Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor (AZD6738) as a Single Agent and in Combination with Palliative Radiation Therapy in Patients with Solid Tumours.” Clinical and Translational Radiation Oncology, vol. 12, Aug. 2018, pp. 16–20. EBSCOhost, https://doi.org/10.1016/j.ctro.2018.06.001.

APA

Martin Forster, Kabir Mohammed, Glen Clack, Clare Peckitt, Simon Smith, Kevin J. Harrington, James Spicer, Udai Banerji, Magnus T. Dillon, J. Guevara, Mark P Saunders, Z. Boylan, & D. Smith. (2018). PATRIOT: A phase I study to assess the tolerability, safety and biological effects of a specific ataxia telangiectasia and Rad3-related (ATR) inhibitor (AZD6738) as a single agent and in combination with palliative radiation therapy in patients with solid tumours. Clinical and Translational Radiation Oncology, 12, 16–20. https://doi.org/10.1016/j.ctro.2018.06.001

Chicago

Martin Forster, Kabir Mohammed, Glen Clack, Clare Peckitt, Simon Smith, Kevin J. Harrington, James Spicer, et al. 2018. “PATRIOT: A Phase I Study to Assess the Tolerability, Safety and Biological Effects of a Specific Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor (AZD6738) as a Single Agent and in Combination with Palliative Radiation Therapy in Patients with Solid Tumours.” Clinical and Translational Radiation Oncology 12 (August): 16–20. doi:10.1016/j.ctro.2018.06.001.